Skip to main content
SpringerLink
Log in

p53 Inactivation is a Rare Event in Familial Breast Tumors Negative for BRCA1 and BRCA2 Mutations

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Germline mutations at BRCA1 or BRCA2 genes result in susceptibility to breast and ovarian cancers. BRCA1- and BRCA2-associated tumors have distinct histologic and molecular phenotypes, as compared to sporadic breast tumors. Typically, a higher grade of malignancy is observed in BRCA-associated cancers. A number of studies have suggested that BRCA1 and BRCA2 proteins are of importance in DNA repair and maintenance of genome integrity, bringing about molecular models of tumor pathogenesis. In particular, alterations at p53 gene have been suggested to be a necessary step in the tumorigenesis of BRCA-associated carcinomas. In fact, BRCA-associated breast cancers have higher p53 mutation frequencies than sporadic ones. At present, very little is known regarding BRCA non-associated familial tumors (termed BRCAx tumors). To our knowledge no data is available on p53 alterations in this sub-group of familial tumors. In this study p53 alteration frequencies were evaluated in 13 BRCA1, 11 BRCA2 and 55 BRCAx breast tumors. Tumor samples were analyzed for p53 gene mutations by PCR-SSCP/direct sequencing, and for p53 protein overexpression by immunohistochemistry (IHC). Altogether, p53 alterations were detected in 54% of BRCA1 tumors compared with 5% of BRCAx tumors. No p53 alteration was found in BRCA2 tumors. While loss of p53 checkpoint control is likely to be an important step in the molecular pathogenesis of BRCA1-associated cancers, our data seem to indicate a p53-independent molecular mechanism underlying BRCAx neoplastic transformation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lakhani SR, Jacquemeier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BAJ, Ford D, Peto J, Stoppa-Lyonnet D, Bignon Y-J, Struewing JP, Spurr NK, Bishop DT, Klijn JGM, Devilee P, Cornelisse CJ, Lasset C, Lenoir G, Bjork Barkadottir R, Egilsson V, Hamann U, Chang-Claude J, Sobol H, Weber B, Stratton MR, Easton DF: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90: 1138-1145, 1998

    Google Scholar 

  2. Lynch BJ, Holden JA, Buys SS, Neuhausen SL, Gaffney DK: Pathobiologic characteristics of hereditary breast cancer. Hum Pathol 29: 1140-1144, 1998

    Google Scholar 

  3. Berns EMJJ, van Staveren IL, Verhoog L, van de Ouweland AMW, Mejer-van Gelder M, Meijers-heijboer H, Portegen H, Foekens JA, Dorssers LCJ, Klijn JGM: Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features. Br J Cancer 85: 538-545, 2001

    Google Scholar 

  4. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallionemi OP, Wilfond B, Borg A, Trent J: Gene-expression profiles in hereditary breast cancer. N Engl J Med 344: 539-548, 2001

    Google Scholar 

  5. Lakhani SR, van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF: The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20: 2310-2318, 2002

    Google Scholar 

  6. van't Veer L, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-535, 2002

    Google Scholar 

  7. Hedenfalk I, Ringner M, Ben-Dor A, Yakhini Z, Chen Y, Chebil G, Ach R, Loman N, Olsson H, Meltzer P, Borg A, Trent J: Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci USA 100: 2532-2537, 2003

    Google Scholar 

  8. Marcus JN, Watson P, Page DL, Narod A, Lenoir GM, Tonin P, Linder-Stephenson L, Salerno G, Conway TA, Lynch HT: Hereditary breast cancer. Pathobiology, prognosis and BRCA1 and BRCA2 gene linkage. Cancer 77: 697-709, 1996

    Google Scholar 

  9. Johannsson OT, Idvall I, Anderson C, Borg Å, Barkardóttir RB, Egilsson V, Olsson H: Tumor biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 33: 362-371, 1997

    Google Scholar 

  10. Armes JE, Egan AJM, Southey MC, Dite GS, McCredie MRE, Hopper JL, Venter DJ: The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations. Cancer 83: 2335-2345, 1998

    Google Scholar 

  11. Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, Hirschaut Y, Pressman P, Rosen PP, Lesser ML, Norton L, Offit K: BRCA-associated breast cancer in young women. J Clin Oncol 16: 1642-1649, 1998

    Google Scholar 

  12. Loman N, Johannson O, Bendahl P-O, Borg Ä, Fernö M, Olsson H: Steroid receptor in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 83: 310-319, 1998

    Google Scholar 

  13. de Bock GH, Tollenaar RA, Papelard H, Cornelisse CJ, Devilee P, van de Vijver MJ: Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients. Br J Cancer 85: 1347-1350, 2001

    Google Scholar 

  14. Eisinger F, Noguès C, Birnbaum D, Jacquemeier J, Sobol H: Low frequency of lymph-node metastasis in BRCA1-associated breast cancer. Lancet 351: 1633-1634, 1998

    Google Scholar 

  15. Marcus JN, Watson P, Page DL, Narod SA, Tonin P, Lenoir GM, Serova O, Lynch HT: BRCA2 hereditary breast cancer patophenotype. Breast Cancer Res Treat 44: 275-277, 1997

    Google Scholar 

  16. Katagiri T, Saito H, Shinohara A, Ogawa H, Kamada N, Nakamura Y, Miki Y: Multiple possible sites of BRCA2 interacting with DNA repair protein RAD51. Genes, Chromosomes Cancer 21: 217-222, 1998

    Google Scholar 

  17. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, Livingston DM: Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88: 265-275, 1997

    Google Scholar 

  18. Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Billia F, Firpo E, Hui CC, Roberts J, Rossant J, Mak TW: The tumor suppressor gene Brca1 is required for embyonic cellular proliferation in the Mouse. Cell 85: 1009-1023, 1996

    Google Scholar 

  19. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A: Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 11: 1226-1241, 1997

    Google Scholar 

  20. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A: Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29: 418-425, 2001

    Google Scholar 

  21. Xu X, Qiao W, Linke SP, Cao L, Li WM, Furth PA, Harris CC, Deng CX: Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet 28: 266-271, 2001

    Google Scholar 

  22. Friedman LS, Thistlethwaite FC, Patel KJ, Yu VPCC, Lee H, Venkitaraman AR, Abel KJ, Carlton MBL, Hunter SM, Colledge WH, Evans MJ, Ponder BAJ: Thymic lymphomas in mice with a truncating mutation in Brca2. Cancer Res 58: 1338-1343, 1998

    Google Scholar 

  23. Hartman AR, Ford JM: BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nature Genet 32: 180-184, 2002

    Google Scholar 

  24. Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, Hutchins A-M, Dite GS, McCredie MRE, Giles GG, Hopper JL, Venter DJ: Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 59: 2011-2017, 1999

    Google Scholar 

  25. Crook T, Brooks LA, Crossland S, Osin P, Barker KT, Waller J, Philp E, Smith PD, Yuluk I, Peto J, Parker G, Allday MJ, Crompton MR, Gusterson BA: p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1-and BRCA2-associated breast tumors. Oncogene 17: 1681-1689, 1998

    Google Scholar 

  26. Ramus SJ, Bobrow LG, Pharoah PDP, Finnigan DS, Fishman A, Altaras M, Harrington PA, Gayther SA, Ponder BAJ, Friedman LS: Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. Genes Chromosomes Cancer 25: 91-96, 1999

    Google Scholar 

  27. Phillips K-A, Nichol K, Ozcelik H, Knight J, Done SJ, Goodwin PJ, Adrulis IL: Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. J Natl Cancer Inst 91: 469-473, 1999

    Google Scholar 

  28. Reedy MB, Hang T, Gallion H, Arnold S, Smith SA: Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCAassociated tumorigenesis. Gynecol Oncol 81: 441-446, 2001

    Google Scholar 

  29. Gretarsdottir S, Thorlacius S, Valgardsdottir R, Gudlaugsdottir S, Sigurdsson S, Steinarssdottir M, Jonasson JG, Anamthawat-Jonsson K, Eyfiörd JE: BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. Cancer Res 58: 859-862, 1998

    Google Scholar 

  30. Martin AM, Kanetsky PA, Amirimani B, Colligon TA, Athanasiadis G, Shih HA, Gerrero MR, Calzone K, Rebbeck TR, Weber BL: Germline TP53 alterations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1? J Med Genet 40: e34, 2003

    Google Scholar 

  31. Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, van de Vijver MJ, Venter D, Freeman A, Antoniou A, Mcguffog L, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BAJ, Futreal PA, Peto J, Stoppa-Lyonnet D, Bignon I-J, Stuewing JP, Bishop DT, Klijn JGM, Devillee P, Cornelisse CJ, Lasset C, Lenoir G, Barkardottir RB, Egilsson V, Hamann U, Chang-Claude J, Sobol H, Weber B, Easton DF, Stratton MR: The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 6: 782-789, 2000

    Google Scholar 

  32. Azzopardi JG, Chepick OF, Hartman WH, Jafarey NA, Llombart-Bosch A, Ozzelo L: Histological typing of breast tumours. International Histological Classification of Tumours, No 2 Geneva, WHO

  33. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. A study of 1409 cases which 359 have been followed for 15 years. Br J Cancer 11: 359-377, 1997

    Google Scholar 

  34. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual. 2nd edn, Cold Spring Harbor Laboratory Press, New York, 1989

    Google Scholar 

  35. Ottini L, D'Amico C, Noviello C, Lauro S, Lalle M, Fornarini G, Colantuoni OA, Pizzi C, Cortesi E, Carlini S, Guadagni F, Bianco AR, Frati L, Contegiacomo A, Mariani-Costantini R: BRCA1 and BRCA2 mutations in central and southern Italian patients. Breast Cancer Res 2: 307-310, 2000

    Google Scholar 

  36. Friedman LS, Gayther SA, Kurosaki T, Gordon D, Noble B, Casey G, Ponder BA, Anton-Culver H: Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 60: 313-319, 1997

    Google Scholar 

  37. Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, King MC: Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nature Genet 8: 399-404, 1994

    Google Scholar 

  38. Ottini L, D'Amico C, Noviello C, Pizzi C, Pagliarulo C, Curia MC, Limite G, Bianco AR, Frati L, Caramia FG, Cama A, Contegiacomo A, Mariani-Costantini R: Novel deletion at codon 1254 of the BRCA1 gene in an Italian breast cancer kindred. Hum Mutat 1 (Suppl): S237-S239, 1998

    Google Scholar 

  39. Geisler JP, Hatterman-Zogg MA, Rathe JA, Lallas TA, Kirby P, Buller RE: Ovarian cancer BRCA1 mutation detection: protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP). Hum Mutat 18: 337-344, 2001

    Google Scholar 

  40. Noguchi S, Kasugai T, Miki Y, Fukutomi T, Emi M, Nomizu T: Clinicopathologic analysis of BRCA1-or BRCA2-associated hereditary breast carcinoma in Japanese women. Cancer 85: 2200-2205, 1999

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Oncogenetics, Division of Surgical, Molecular and Ultrastructural Pathology, Department of Oncology, University Hospital of Pisa, University of Pisa, Pisa, Italy

    Elisa Sensi, Mariella Tancredi, Paolo Aretini, Giovanna Cipollini, A. Giuseppe Naccarato, Paolo Viacava, Generoso Bevilacqua & Maria A. Caligo

Authors
  1. Elisa Sensi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mariella Tancredi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paolo Aretini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giovanna Cipollini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Giuseppe Naccarato
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Paolo Viacava
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Generoso Bevilacqua
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maria A. Caligo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sensi, E., Tancredi, M., Aretini, P. et al. p53 Inactivation is a Rare Event in Familial Breast Tumors Negative for BRCA1 and BRCA2 Mutations. Breast Cancer Res Treat 82, 1–9 (2003). https://doi.org/10.1023/B:BREA.0000003836.91844.b5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:BREA.0000003836.91844.b5

Search

Navigation